Age‐related diagnostic threshold of anti‐Müllerian hormone for polycystic ovarian syndrome. Issue 3 (29th December 2020)

• Record Type: Journal Article
• Authors: Kakkad, Vivek; Reddy, Nellepalli Sanjeeva; Nihlani, Harsh; Gundewar, Tejas
• Is Part Of: International journal of gynaecology and obstetrics. Volume 153:Issue 3(2021)
• Page Start: 443
• Page End: 448
• Publication Date: 2020-12-29
• Subjects: anti‐Müllerian hormone -- diagnosis -- India -- polycystic ovarian syndrome -- Rotterdam criteria; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1002/ijgo.13515
• Languages: English
• ISSNs: 0020-7292

Abstract

ABSTRACT: OBJECTIVE: To ascertain the threshold value for anti‐Müllerian hormone (AMH) in the diagnosis of polycystic ovarian syndrome (PCOS) in an Indian population. METHODS: A retrospective observational study was carried out on infertile women at the Department of Reproductive Medicine and Surgery at a tertiary hospital from January 2017 to November 2019. Serum AMH was analyzed with Access AMH chemiluminescent immunoassay. Receiver operating characteristic curves were used to calculate the diagnostic threshold value of serum AMH in two age groups: 20–29 and 30–39 years. RESULTS: Of 688 women, 200 (29.1%) were diagnosed with PCOS by the Rotterdam criteria: 98/282 (34.8%) aged 20–29 years and 102/406 (25.4%) aged 30–39 years. Mean serum AMH was 5.07 ± 3.97 and 4.330 ± 7.15 ng/ml in women aged 20–29 and 30–39 years, respectively. A threshold value of serum AMH above 3.75 ng/ml was predictive of PCOS by Youden's J statistics in the entire cohort, whereas it was 5.46 and 3.46 ng/ml in women aged 20–29 and 30–39 years, respectively. CONCLUSION: Serum AMH of 5.46 and 3.46 ng/ml in women aged 20–29 and 30–39 years, respectively, can be used to diagnose PCOS when there is a diagnostic dilemma in the Rotterdam criteria. Synopsis: Different levels of serum anti‐Müllerian hormone can be used to diagnose polycystic ovarian syndrome when there is a diagnostic dilemma in the Rotterdam criteria.